At SABCS 2025, studies show some patients with early-stage breast cancer can skip steps like SLNB or MRI without...
On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with...
Finding a way to therapeutically target the so-called “undruggable” cancer proteins has long been a holy grail of researchers...
The Affordable Care Act, which was enacted in 2010 and recently survived an effort to dismantle it, was the...
Identifying ways to increase the proportion of patients with melanoma who have clinically meaningful and durable responses to immune...
Former Vice President Joe Biden returned to the stage at the American Association for Cancer Research (AACR) Annual Meeting...
Now that a plethora of clinical trials have established positive responses from immunotherapies—immune checkpoint inhibitors, in particular—in patients with...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the...
April symbolizes a progressive time for cancer researchers around the world. From April 1-5, over 20,000 cancer scientists will...
As part of a growing public affairs program, the American Association for Cancer Research is excited to once again...
A big career fair can be somewhat intimidating, so we asked some hiring experts for their advice on how...